Arellano Navarro Consuelo Estephani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arellano Navarro Consuelo Estephani has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Edgar Carlos Jarillo Soto
Universidad Autónoma Metropolitana-Xochimilco. Mexico City, Mexico
1 shared publication Ericka Giovanna Gonzalez Gonzalez
1 shared publication- Juan Carlos Rivas Rodríguez1 shared publication
- Karalam Guadalupe Torres Jiménez1 shared publication
- María Gilma Arroyave-Loaiza
Facultad de Contaduría y Administración, Universidad Nacional Autónoma de México. Mexico City, Mexico. Secretaría de Salud de la Ciudad de México. Mexico City, Mexico
1 shared publication - Melina Samara Rangel Tristán1 shared publication
Latest Publications
- Open Access
- 17 September 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (5, sept-oc) , 732-740
Proposal to estimate the required resources for healthcare
Objective. To present a proposal to estimate healthcare resource requirements for the population with no social security in Mexico City and the domestic projection, including access and coverage. Materials and methods. The gross domestic product percentage for healthcare is calculated using the Medical-Technical Baseline Cost (MTBC) or the Medical Economic Card (MEC) standard according to diagnosis and care treatment for the population with no social security, thus projecting the prospective resource requirements. Results. There is a shortfall of resources for 2024; the prospective per capita for the first level of healthcare is $3,813 and the historical one is $1,933; and the corresponding values for the second level are $4,430 and $3,861. The %GDP-healthcare for Mexico City in 2024 exhibits a 42% difference between the historical and prospective categories. The shortfall of resources for the three levels of healthcare in the entire country is 19%. Conclusions. The prospective budget makes it possible to calculate healthcare resource requirements with a higher degree of certainty and graduality.
- 17 September 2024
- Published by Instituto Nacional de Salud Publica in Salud Pública de México
- Vol. 66 (5, sept-oc) , 732-740
Open AccessProposal to estimate the required resources for healthcare
Objective. To present a proposal to estimate healthcare resource requirements for the population with no social security in Mexico City and the domestic projection, including access and coverage. Materials and methods. The gross domestic product percentage for healthcare is calculated using the Medical-Technical Baseline Cost (MTBC) or the Medical Economic Card (MEC) standard according to diagnosis and care treatment for the population with no social security, thus projecting the prospective resource requirements. Results. There is a shortfall of resources for 2024; the prospective per capita for the first level of healthcare is $3,813 and the historical one is $1,933; and the corresponding values for the second level are $4,430 and $3,861. The %GDP-healthcare for Mexico City in 2024 exhibits a 42% difference between the historical and prospective categories. The shortfall of resources for the three levels of healthcare in the entire country is 19%. Conclusions. The prospective budget makes it possible to calculate healthcare resource requirements with a higher degree of certainty and graduality.
- Open Access
- 2 September 2024
- Published by Brazilian Journals in South Florida Journal of Development
- Vol. 5 (9) , e4339
Post-hypoxic myoclonus (Lance-Adams Syndrome) in post-cardiorespiratory arrest, a case presentation in elderly
A clinical case report is presented of an elderly adult recovering from cardiac arrest who developed generalized myoclonus or Lance Adams syndrome in a tertiary care hospital. Myoclonus is defined as a sudden, brief muscle contraction (1). The Lance Adams Syndrome is a form of post- hypoxic myoclonus, characterized by action myoclonus that typically involve the trunk, face, and extremities, and whose onset is days to weeks after a hypoxic brain injury. (2) The incidence of post-hypoxic myoclonus is 1. 3 cases per 100,000 people per year, so its differential diagnosis represents a challenge. The etiology may be secondary to cardiorespiratory arrest, anesthetic and surgical accidents, in addition to heart disease and drug overdose. Acute post-hypoxic myoclonus begins hours after the injury, sometimes begins as myoclonic status epilepticus, and if the patient survives, he will progress to a chronic phase with a poor or low life expectancy. Treatment is controversial, several articles agree that patients have shown better response to Levetiracetam, Magnesium Valproate, Lacosamide and Clonazepam.
- 2 September 2024
- Published by Brazilian Journals in South Florida Journal of Development
- Vol. 5 (9) , e4339
Open AccessPost-hypoxic myoclonus (Lance-Adams Syndrome) in post-cardiorespiratory arrest, a case presentation in elderly
A clinical case report is presented of an elderly adult recovering from cardiac arrest who developed generalized myoclonus or Lance Adams syndrome in a tertiary care hospital. Myoclonus is defined as a sudden, brief muscle contraction (1). The Lance Adams Syndrome is a form of post- hypoxic myoclonus, characterized by action myoclonus that typically involve the trunk, face, and extremities, and whose onset is days to weeks after a hypoxic brain injury. (2) The incidence of post-hypoxic myoclonus is 1. 3 cases per 100,000 people per year, so its differential diagnosis represents a challenge. The etiology may be secondary to cardiorespiratory arrest, anesthetic and surgical accidents, in addition to heart disease and drug overdose. Acute post-hypoxic myoclonus begins hours after the injury, sometimes begins as myoclonic status epilepticus, and if the patient survives, he will progress to a chronic phase with a poor or low life expectancy. Treatment is controversial, several articles agree that patients have shown better response to Levetiracetam, Magnesium Valproate, Lacosamide and Clonazepam.